Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway

Biochemistry and Cell Biology

Volumn 90, Issue 4, 2012, Pages 521-531

  Ha, Jun ^a   Zhao, Li ^a   Zhao, Qing ^a   Yao, Jing ^a   Zhu, Bin Bin ^a   Lu, Na ^a   Ke, Xue ^a   Yang, Hui Ying ^a   Li, Zhiyu ^a   You, Qi Dong ^a   Guo, Qing Long ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; colorectal cancer cells; cyclooxygenase 2; oroxylin A; synergistic effect

Indexed keywords

5-FLUOROURACIL; COLORECTAL CANCER CELL; CYCLOOXYGENASE 2; OROXYLIN A; SYNERGISTIC EFFECT;

CELL PROLIFERATION; CYTOLOGY; DISEASES; TUMORS;

CELLS;

CYCLOOXYGENASE 2; FLUOROURACIL; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OROXYLIN A; PROCASPASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; FEMALE; FLAVONOIDS; FLUOROURACIL; HT29 CELLS; HUMANS; MICE; MICE, NUDE; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 84863003468     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/o2012-005     Document Type: Article

References (31)

1. Anderson S.M. 2011. Laboratory methods for KRAS mutation analysis. Expert Rev. Mol. Diagn. 11 (6): 635-642. 10.1586/erm.11.42 21745016
2. Chang Y.W. Jakobi R. McGinty A. Foschi M. Dunn M.J. Sorokin A. 2000. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol. Cell. Biol. 20 (22): 8571-8579. 10.1128/MCB.20.22.8571-8579.2000 11046152
3. Chen Y. Yang L. Lee T.J. 2000. Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation. Biochem. Pharmacol. 59 (11): 1445-1457. 10.1016/S0006-2952(00)00255-0 10751555 (Pubitemid 30177363)
4. Chou T.C. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (3): 621-681. 10.1124/pr.58.3.10 16968952 (Pubitemid 44403686)
5. Chou T.C. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70 (2): 440-446. 10.1158/0008-5472.CAN-09-1947 20068163
6. Dang C.T. Shapiro C.L. Hudis C.A. 2002. Potential role of selective COX-2 inhibitors in cancer management. Oncology (Williston Park), 16 (5 Suppl. 4): 30-36. 12102578
7. Fan F. Wey J.S. McCarty M.F. Belcheva A. Liu W. Bauer T.W. et al. 2005. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene, 24 (16): 2647-2653. 10.1038/sj.onc.1208246 15735759 (Pubitemid 40593092)
8. Gao Y. Lu N. Ling Y. Chen Y. Wang L. Zhao Q. et al. 2010. Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. J. Cancer Res. Clin. Oncol. 136 (5): 667-675. 10.1007/s00432-009-0705-2 19888602
9. Gately S. 2000. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 19 (1-2): 19-27. 10.1023/A:1026575610124 11191059 (Pubitemid 32004688)
10. Horinaka M. Yoshida T. Shiraishi T. Nakata S. Wakada M. Sakai T. 2006. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Ther. 5 (4): 945-951. 10.1158/1535-7163.MCT-05-0431 16648565 (Pubitemid 43724594)
11. Hwang J.T. Ha J. Park O.J. 2005. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem. Biophys. Res. Commun. 332 (2): 433-440. 10.1016/j.bbrc.2005.04.143 15896711 (Pubitemid 40731495)
12. Hwang J.T. Kim Y.M. Surh Y.J. Baik H.W. Lee S.K. Ha J. Park O.J. 2006. Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res. 66 (20): 10057-10063. 10.1158/0008-5472.CAN-06-1814 17047069 (Pubitemid 44672059)
13. Hwang J.T. Ha J. Park I.J. Lee S.K. Baik H.W. Kim Y.M. Park O.J. 2007. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett. 247 (1): 115-121. 10.1016/j.canlet.2006.03.030 16797120 (Pubitemid 46001507)
14. Koehne C.H. Dubois R.N. 2004. COX-2 inhibition and colorectal cancer. Semin. Oncol. 31: 12-21. 15252926 (Pubitemid 38879410)
15. Li H.B. Chen F. 2005. Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J. Chromatogr. A, 1074 (1-2): 107-110. 10.1016/j.chroma.2005.03.088 15941045 (Pubitemid 40615049)
16. Li H.N. Nie F.F. Liu W. Dai Q.S. Lu N. Qi Q. et al. 2009. Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo. Toxicology, 257 (1-2): 80-85. 10.1016/j.tox.2008.12.011 19135124
17. Liu W. Mu R. Nie F.F. Yang Y. Wang J. Dai Q.S. et al. 2009. MAC-related mitochondrial pathway in oroxylin-A-induced apoptosis in human hepatocellular carcinoma HepG2 cells. Cancer Lett. 284 (2): 198-207. 10.1016/j.canlet.2009.04. 021 19473757
18. Malaplate-Armand C. Florent-Bechard S. Youssef I. Koziel V. Sponne I. Kriem B. et al. 2006. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 23 (1): 178-189. 10.1016/j.nbd.2006.02.010 16626961 (Pubitemid 43922461)
19. Mathieu A. Remmelink M. D’Haene N. Penant S. Gaussin J.F. Van Ginckel R. et al. 2004. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer, 101 (8): 1908-1918. 10.1002/cncr.20571 15386340 (Pubitemid 39328201)
20. Mu R. Qi Q. Gu H. Wang J. Yang Y. Rong J. et al. 2009. Involvement of p53 in oroxylin A-induced apoptosis in cancer cells. Mol. Carcinog. 48 (12): 1159-1169. 10.1002/mc.20570 19626645
21. Ogino M. Minoura S. 2001. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents. Int. J. Clin. Oncol. 6 (2): 84-89. 10.1007/PL00012088 11706755 (Pubitemid 32422397)
22. Rockwell P. Martinez J. Papa L. Gomes E. 2004. Redox regulates COX-2 upregulation and cell death in the neuronal response to cadmium. Cell. Signal. 16 (3): 343-353. 10.1016/j.cellsig.2003.08.006 14687664 (Pubitemid 37542409)
23. Shaw R.J. Kosmatka M. Bardeesy N. Hurley R.L. Witters L.A. DePinho R.A. Cantley L.C. 2004. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A. 101 (10): 3329-3335. 10.1073/pnas.0308061100 14985505 (Pubitemid 38338195)
24. Smith W.L. DeWitt D.L. Garavito R.M. 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (1): 145-182. 10.1146/annurev.biochem.69.1.145 10966456
25. Subbaramaiah K. Dannenberg A.J. 2003. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24 (2): 96-102. 10.1016/S0165-6147(02)00043-3 12559775 (Pubitemid 36135884)
26. Sun Y. Lu N. Ling Y. Gao Y. Chen Y. Wang L. et al. 2009. Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Eur. J. Pharmacol. 603 (1-3): 22-28. 10.1016/j.ejphar.2008.12.008 19100732
27. Surh Y.J. Chun K.S. Cha H.H. Han S.S. Keum Y.S. Park K.K. Lee S.S. 2001. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 480-481: 243-268. 11506818 (Pubitemid 32744832)
28. Yang Y. Hu Y. Gu H.Y. Lu N. Liu W. Qi Q. et al. 2008. Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J. Pharm. Pharmacol. 60 (11): 1459-1463. 18957166
29. Yoshikawa R. Kusunoki M. Yanagi H. Noda M. Furuyama J.I. Yamamura T. Hashimoto-Tamaoki T. 2001. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 61 (3): 1029-1037. 11221829 (Pubitemid 32174421)
30. Yun H. Lee M. Kim S.S. Ha J. 2005. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J. Biol. Chem. 280 (11): 9963-9972. 10.1074/jbc.M412994200 15640157 (Pubitemid 40395845)
31. Zhao L. Chen Z. Wang J. Yang L. Zhao Q. Wang J. et al. 2010. Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother. Pharmacol. 65 (3): 481-489. 10.1007/s00280-009-1053-2 19585117